Jensen-Jarolim, Erika
Jensen, Sebastian Alexander
Bergmann, Karl-Christian
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 2 May 2023
Accepted: 22 May 2023
First Online: 30 June 2023
Conflict of interest
: E. Jensen-Jarolim is a shareholder in Biomedical International R + D GmbH, Vienna, and co-inventor on patent EP 2894478 A1 “Method and means for diagnosing and treating allergy” of Biomedical Int. R + D GmbH. She is a consultant for Bencard Allergie GmbH and Allergy Therapeutics Ltd. and receives lecture fees from Bencard Allergie GmbH, Sanofi, Germania Pharmaceutics, Meda, Menarini, Novartis, Santen, Sanofi. S.A. Jensen and K.-C. Bergmann declare no conflict of interest with the content of the publication. K.-C. Bergmann is a member of advisory boards for, and receives speaking fees from GSK, AstraZeneca, Novartis, Sanofi, LETI.